REVIEW ON WHY RANITIDINE WAS BANNED IN INDIA
G.V.K.S. Abhinav*, Sushma Sandaka, Lokesh Dara, Dr. Naga Subrahmanyam S., Shaik Irshad, Lokesh Masagiri
Indian doctors have advised patients to avoid over the counter(OTC) use of popular antacid ranitidine, following concerns over its contamination by cancer causing substances, with the central drug standard control organisation (CDSCO) now having started the process of checking for any adverse reactions of the drug. State bodies have asked to verify product, and take appropriate measures for patient safety. Ranitidine is a generic name and sold under the trade name Zantac among others, is medication which decreases stomach acid production, it's a drug which is used in treatment of peptic ulcer disease, gastroesophageal reflux disease, and zollinger ellison syndrome. Indian pharma impacted by regulatory headwinds for ranitidine, ranitidine contributors 5% of solara’s revenue; company has a presence in ratidine’s alternative. Impact on pharma companies, global formulation market of ranitidine, and their details will be discussed in this article.
Keywords: Ranitidine, gastroesophageal reflux disease, zantac, zollinger-ellison.
[Full Text Article]